Oculis Stock Price Expected to Rise, Analyst Says

Needham & Company LLC lifts price target on Oculis shares

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies, saw its price target raised from $36 to $40 by Needham & Company LLC. The firm maintained its "buy" rating on the stock, citing the company's promising pipeline of treatments targeting retinal and neuro-ophthalmic diseases.

Why it matters

Oculis is a relatively young biotech company, but its innovative approach to delivering therapeutics to the back of the eye through topical or nasal administration has generated significant investor interest. This price target increase from a respected analyst firm suggests growing confidence in the company's ability to advance its pipeline and potentially offer alternatives to current standard-of-care treatments that require intravitreal injections.

The details

In a research note, Needham & Company LLC cited Oculis' progress with its lead candidate OCS-01, a topical dexamethasone formulation targeting diabetic macular edema, as well as its other pipeline assets OCS-05 for acute optic neuritis and idiopathic intracranial hypertension, and OC-02, a nasal spray formulation of varenicline for dry eye disease. The firm believes these programs have significant commercial potential if they continue to advance through clinical development.

  • Needham & Company LLC issued the updated price target and "buy" rating on March 4, 2026.

The players

Oculis

A clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies, including treatments targeting retinal and neuro-ophthalmic diseases.

Needham & Company LLC

An investment banking and asset management firm that provides research coverage and analysis on Oculis.

Got photos? Submit your photos here. ›

The takeaway

Oculis' innovative approach to developing topical and nasal administration treatments for eye diseases has caught the attention of Wall Street, with a respected analyst firm now projecting significant upside potential for the company's stock price. This reflects growing confidence in Oculis' ability to advance its pipeline and potentially disrupt the current standard of care in ophthalmology.